{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T17:40:03Z","timestamp":1750527603313,"version":"3.41.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Myelodysplastic syndrome includes a broad range of myeloid neoplasms characterized by cytopenia and morphologic dysplasia. Recently, 2 new classification systems emerged to further define how these diseases are diagnosed and risk stratified. This review compares these models, provides detailed approaches, and reveals practical ways to move forward in clinical practice of myelodysplastic syndrome diagnosis.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000659","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T14:06:57Z","timestamp":1684332417000},"page":"122-129","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Updates in Classification of Myelodysplastic Syndrome"],"prefix":"10.1097","volume":"29","author":[{"given":"Mina L.","family":"Xu","sequence":"first","affiliation":[{"name":"Yale University, New Haven, CT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"Hasserjian","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Harvard Medical School, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20250621","first-page":"E420","article-title":"Myelodysplastic syndromes with no somatic mutations detected by next-generation sequencing display similar features to myelodysplastic syndromes with detectable mutations","volume":"96","year":"2021","journal-title":"Am J Hematol"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","year":"2015","journal-title":"Blood"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"73483","DOI":"10.18632\/oncotarget.19008","article-title":"Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1182\/blood-2016-07-728766","article-title":"Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11899-012-0140-3","article-title":"Dysplasia has a differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors","volume":"7","year":"2012","journal-title":"Curr Hematol Malig Rep"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","year":"2022","journal-title":"Blood"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","year":"2022","journal-title":"Leukemia"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","article-title":"Clinical significance of somatic mutation in unexplained blood cytopenia","volume":"129","year":"2017","journal-title":"Blood"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2021011304","article-title":"Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal","volume":"139","year":"2022","journal-title":"Blood"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1002\/cncr.34119","article-title":"Time to blur the blast boundaries","volume":"128","year":"2022","journal-title":"Cancer"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.1182\/bloodadvances.2020002206","article-title":"Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features","volume":"4","year":"2020","journal-title":"Blood Adv"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2018-08-867333","article-title":"The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis","volume":"133","year":"2019","journal-title":"Blood"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1200\/JCO.20.01659","article-title":"Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes","volume":"39","year":"2021","journal-title":"J Clin Oncol"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1182\/blood.2020005488","article-title":"Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes","volume":"136","year":"2020","journal-title":"Blood"},{"key":"bib16-20250621","first-page":"1","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","year":"2022","journal-title":"NEJM Evid"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ccr.2014.03.036","article-title":"Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo","volume":"25","year":"2014","journal-title":"Cancer Cell"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood.2020004850","article-title":"SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS","volume":"136","year":"2020","journal-title":"Blood"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1038\/ncomms6901","article-title":"Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndrome","volume":"6","year":"2015","journal-title":"Nat Commun"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","year":"2017","journal-title":"N Engl J Med"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/s41375-018-0351-2","article-title":"TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups","volume":"33","year":"2019","journal-title":"Leukemia"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","article-title":"TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML","volume":"6","year":"2022","journal-title":"Blood Adv"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/leu.2015.304","article-title":"Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes","volume":"30","year":"2016","journal-title":"Leukemia"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/cncr.34535","article-title":"TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity","volume":"129","year":"2023","journal-title":"Cancer"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","year":"2020","journal-title":"Nat Med"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","year":"2022","journal-title":"Blood"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/sj.leu.2404747","article-title":"Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin","volume":"21","year":"2007","journal-title":"Leukemia"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1038\/s41375-021-01190-9","article-title":"Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia","volume":"35","year":"2021","journal-title":"Leukemia"},{"key":"bib29-20250621","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/sj.leu.2405076","article-title":"Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-\/hypercellular MDS by international prognostic scoring system, cytogenetic and genetic studies","volume":"22","year":"2008","journal-title":"Leukemia"},{"key":"bib30-20250621","doi-asserted-by":"crossref","first-page":"63177","DOI":"10.18632\/oncotarget.11050","article-title":"Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS)","volume":"7","year":"2016","journal-title":"Oncotarget"},{"key":"bib31-20250621","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.3324\/haematol.2015.130112","article-title":"Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes","volume":"100","year":"2015","journal-title":"Haematologica"},{"key":"bib32-20250621","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.3390\/cancers14122984","article-title":"Bone marrow fibrosis at diagnosis and during the course of disease is associated with TP53 mutations and adverse prognosis in primary myelodysplastic syndrome","volume":"14","year":"2022","journal-title":"Cancers (Basel)"},{"key":"bib33-20250621","first-page":"763","article-title":"Bone marrow fibrosis impact on response to azacytidine in myelodysplastic syndromes","volume":"54","year":"2022","journal-title":"Pathology"},{"key":"bib34-20250621","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/modpathol.2013.187","article-title":"Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems","volume":"27","year":"2014","journal-title":"Mod Pathol"},{"key":"bib35-20250621","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/ajcp\/aqx043","article-title":"Myelodysplastic syndrome, unclassifiable (MDS-U) with 1% blasts is a distinct subgroup of MDS-U with a poor prognosis","volume":"148","year":"2017","journal-title":"Am J Clin Pathol"},{"key":"bib36-20250621","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","article-title":"Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study","volume":"18","year":"2017","journal-title":"Lancet Oncol"},{"key":"bib37-20250621","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s11899-021-00636-2","article-title":"The emerging role of hematopathologists and molecular pathologists in detection, monitoring and management of myeloid neoplasms with germline predisposition","volume":"16","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"key":"bib38-20250621","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.beha.2014.11.004","article-title":"Genetic predisposition syndromes; when should they be considered in the work-up of MDS?","volume":"28","year":"2015","journal-title":"Best Pract Res Clin Haematol"},{"key":"bib39-20250621","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1182\/bloodadvances.2021005117","article-title":"Juvenile myelomonocytic leukemia in the molecular era: a clinician's guide to diagnosis, risk stratification, and treatment","volume":"5","year":"2021","journal-title":"Blood Adv"},{"key":"bib40-20250621","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2559.2011.04156.x","article-title":"Morphological differentiation of severe aplastic anaemia from hypocellular refractory cytopenia of childhood: reproducibility of histopathological diagnostic criteria","volume":"61","year":"2012","journal-title":"Histopathology"},{"key":"bib41-20250621","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s12185-016-1965-7","article-title":"The current perspective of low-grade myelodysplastic syndrome in children","volume":"103","year":"2016","journal-title":"Int J Hematol"},{"key":"bib42-20250621","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1309\/50GWDKVWU3VWL5XW","article-title":"Aplastic anemia and monosomy 7\u2013associated dysmegakaryocytopoiesis","volume":"126","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"bib43-20250621","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood-2017-09-765214","article-title":"How I treat myelodysplastic syndromes of childhood","volume":"131","year":"2018","journal-title":"Blood"},{"key":"bib44-20250621","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1038\/s41591-021-01511-6","article-title":"Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9\/SAMD9L syndromes","volume":"27","year":"2021","journal-title":"Nat Med"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000659","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T17:03:05Z","timestamp":1750525385000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000659","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"type":"electronic","value":"1540-336X"},{"type":"print","value":"1528-9117"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}